Pyxis Oncology (PYXS) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed SIGA Technologies (SIGA) over the past year, losing 21.2% versus a loss of 61.4%. Over five years, SIGA leads with a -54.1% price change compared with -82.9% for PYXS. SIGA Technologies is the larger company by market cap ($238.5 million vs $234.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | SIGA |
|---|---|---|
| Share price | $1.97 | $3.32 |
| Market cap | $234.73M | $238.55M |
| 1-day change | -2.24% | +1.84% |
| YTD return | +74.78% | -46.64% |
| 1-year return | -21.18% | -61.37% |
| 5-year return | -82.92% | -54.15% |
| Forward P/E | — | 3.07 |
| EPS (TTM) | $-1.40 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $8.55 |
| 52-week low | $1.03 | $2.83 |
| Distance from 52-week high | -64.59% | -61.17% |
| Analyst consensus | none | none |
| Avg. price target upside | +341.22% | — |
| Average volume | 1.25M | 726.50K |
| Shares outstanding | 119.46M | 71.85M |
| Employees | 56 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYXS has outperformed SIGA by 40.2 percentage points over the past year.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
PYXS vs SIGA FAQ
Which is bigger, Pyxis Oncology or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $238.55M compared with $234.73M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, PYXS or SIGA?
PYXS returned -21.18% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Pyxis Oncology and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.